ALVO Alvotech IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1898416 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $586.32M | $489.68M | $91.43M | $83.03M | $36.77M |
| Cost of revenue | $235.56M | $185.31M | $160.86M | $64.09M | $0 |
| Gross profit | $350.76M | $304.37M | -$69.42M | $18.93M | $36.77M |
| R&D expense | $184.19M | $171.31M | $210.83M | $180.62M | $191.01M |
| SG&A expense | $90.95M | $65.71M | $76.56M | $186.74M | $84.13M |
| Operating income | $78.21M | $69.64M | -$354.86M | -$346.44M | -$235.46M |
| Interest expense | $149.19M | $303.17M | $267.16M | $188.42M | $117.36M |
| Pretax income | $136.35M | -$217.56M | -$651.05M | -$551.65M | -$149.20M |
| Income tax | $108.43M | $14.30M | -$99.32M | -$38.07M | -$47.69M |
| Net income | $27.92M | -$231.86M | -$551.73M | -$513.58M | -$101.50M |
| EBITDA | $116.06M | $100.94M | -$330.65M | -$326.03M | -$217.26M |
| EPS (basic) | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 |
| EPS (diluted) | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 |
| Weighted avg. shares (diluted) | 291.34M | 267.92M | 227.26M | 197.72M | 110.67M |
| Balance sheet | |||||
| Cash & equivalents | $172.36M | $51.43M | $11.16M | $66.43M | $17.56M |
| Receivables | $69.74M | $160.22M | $41.29M | $32.97M | $29.40M |
| Inventory | $220.05M | $127.89M | $74.43M | $71.47M | $39.06M |
| Current assets | $574.01M | $455.02M | $194.84M | $230.74M | $119.82M |
| PP&E, netmay include right-of-use assets (IFRS) | $356.40M | $284.55M | $236.78M | $220.59M | $78.53M |
| Goodwill | $12.84M | $11.33M | $12.06M | $11.64M | $12.37M |
| Intangibles | $81.83M | $20.62M | $19.08M | $25.65M | $21.51M |
| Total assets | $1.49B | $1.22B | $950.09M | $828.44M | $597.98M |
| Current liabilities | $304.08M | $193.40M | $260.95M | $167.29M | $111.84M |
| Short-term debt | $36.92M | $32.70M | $38.02M | $19.92M | $2.77M |
| Long-term debt | $1.26B | $1.04B | $922.13M | $744.65M | $398.14M |
| Total debt | $1.30B | $1.07B | $960.16M | $764.57M | $400.91M |
| Total liabilities | $1.77B | $1.63B | $1.88B | $1.39B | $733.59M |
| Shareholders' equity | -$284.49M | -$412.77M | -$932.49M | -$564.42M | -$135.61M |
| Net debt | $1.13B | $1.02B | $949.00M | $698.14M | $383.36M |
| Shares outstanding | 312.02M | 301.81M | 266.82M | 252.16M | 893,060 |
| Cash flow statement | |||||
| Operating cash flow | -$50.20M | -$236.84M | -$312.19M | -$312.39M | -$228.17M |
| Capital expenditure | $64.47M | $53.66M | $33.23M | $37.88M | $20.46M |
| Free cash flow | -$114.67M | -$290.50M | -$345.42M | -$350.27M | -$248.63M |
| Investing cash flow | -$104.22M | -$18.87M | -$46.34M | -$63.54M | -$40.63M |
| Financing cash flow | $270.83M | $297.31M | $301.32M | $424.91M | $254.83M |
| Depreciation & amortization | $37.85M | $31.30M | $24.21M | $20.41M | $18.20M |
| Stock-based compensation | $7.38M | $7.63M | $18.03M | $10.32M | $0 |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.